Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Medrxiv : the Preprint Server for Health Sciences
|
April 16, 2025
A Phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/Ref-1 in Cancer
Mark R Kelley, Jun Wan, Sheng Liu, et al.
The Oncologist
|
December 22, 2025
A Phase I study targeting the APE1/ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/ref-1 in Cancer
Mark R Kelley, Jun Wan, Sheng Liu, et al.
Journal for Immunotherapy of Cancer
|
January 12, 2025
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer
Nehal J Lakhani, Daphne Stewart, Debra L Richardson, et al.
Haematologica
|
April 10, 2025
Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study
Tae Min Kim, Nehal J Lakhani, Jacob Soumerai, et al.
Cancer Biology & Therapy
|
December 17, 2005
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors
William L Dahut, Nehal J Lakhani, James L Gulley, et al.
Targeted Oncology
|
March 27, 2025
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors
Cathy Eng, Nehal J Lakhani, Philip A Philip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma
David H Aggen, Meredith McKean, Jean H Hoffman-Censits, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Vivek Subbiah, Sant P Chawla, Anthony P Conley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, et al.
The Lancet. Oncology
|
November 18, 2021
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
Nehal J Lakhani, Laura Q M Chow, Justin F Gainor, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Medrxiv : the Preprint Server for Health Sciences
|
April 16, 2025
A Phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/Ref-1 in Cancer
Mark R Kelley, Jun Wan, Sheng Liu, et al.
The Oncologist
|
December 22, 2025
A Phase I study targeting the APE1/ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/ref-1 in Cancer
Mark R Kelley, Jun Wan, Sheng Liu, et al.
Journal for Immunotherapy of Cancer
|
January 12, 2025
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer
Nehal J Lakhani, Daphne Stewart, Debra L Richardson, et al.
Haematologica
|
April 10, 2025
Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study
Tae Min Kim, Nehal J Lakhani, Jacob Soumerai, et al.
Cancer Biology & Therapy
|
December 17, 2005
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors
William L Dahut, Nehal J Lakhani, James L Gulley, et al.
Targeted Oncology
|
March 27, 2025
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors
Cathy Eng, Nehal J Lakhani, Philip A Philip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma
David H Aggen, Meredith McKean, Jean H Hoffman-Censits, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Vivek Subbiah, Sant P Chawla, Anthony P Conley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, et al.
The Lancet. Oncology
|
November 18, 2021
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
Nehal J Lakhani, Laura Q M Chow, Justin F Gainor, et al.
Page
of 3